Gsa Capital Partners LLP Viking Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 5,522 shares of VKTX stock, worth $159,420. This represents 0.02% of its overall portfolio holdings.
Number of Shares
5,522
Previous 8,160
32.33%
Holding current value
$159,420
Previous $517,000
57.06%
% of portfolio
0.02%
Previous 0.04%
Shares
21 transactions
Others Institutions Holding VKTX
# of Institutions
467Shares Held
65.8MCall Options Held
5.84MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$294 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$174 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$142 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$74.9 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$62.3 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.21B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...